EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nuvation Bio's enterprise value is $222.88 Mil.
Nuvation Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $7.87 Mil. Therefore, Nuvation Bio's EV-to-Revenue for today is 28.31.
The historical rank and industry rank for Nuvation Bio's EV-to-Revenue or its related term are showing as below:
NUVB'
s EV-to-Revenue Range Over the Past 10 Years
Min: 8.43 Med: 56.43 Max: 245.88
Current: 28.31
During the past 5 years, the highest EV-to-Revenue of Nuvation Bio was 245.88. The lowest was 8.43. And the median was 56.43.
NUVB's EV-to-Revenue is ranked worse than 74.27% of 987
companies
in the Biotechnology industry
Industry Median: 6.76
vs NUVB: 28.31
As of today (2025-05-09), Nuvation Bio's stock price is $2.09.
Nuvation Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.03. Therefore, Nuvation Bio's PS Ratio for today is 80.38.
Nuvation Bio EV-to-Revenue Historical Data
The historical data trend for Nuvation Bio's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nuvation Bio's EV-to-Revenue
For the Biotechnology subindustry, Nuvation Bio's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's EV-to-Revenue falls into.
Nuvation Bio's current Enterprise Value is $222.88 Mil.
Nuvation Bio's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.87 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NYSE:NUVB) EV-to-Revenue Explanation
Nuvation Bio's share price for today is $2.09.
Nuvation Bio's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Nuvation Bio's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NUVB has been successfully added to your 